Olon discloses to be in a late-stage phase of development of TUCATINIB, (NCE-1 APRILl 24), being already in the qualification process of the product.

In line with the solid commercial strategy of early enetring in the market and competitive time to market, the company has implemented the technological manufacturing platform able to meet customer’s request for TUCATINIB. 

TUCATINIB is an API for the treatment of several solid tumors and the sythesis route presents very high complexity